Europe Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome), By Type of Therapy By End User, By Country and Growth Forecast, 2022 - 2

Europe Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome), By Type of Therapy By End User, By Country and Growth Forecast, 2022 - 2028

The Europe Lysosomal Disease Treatment Market would witness market growth of 5.7% CAGR during the forecast period (2022-2028).

Any lysosomal substrate stored causes an increase in the size and quantity of lysosomes in the lysosomal compartment. However, lysosomal compartment expansion alone does not result in mechanical damage that kills cells; other, more subtle pathways result in cell malfunction and ultimately cell death. For instance, various theories have been put out in recent years to explain why cholesterol deposition in the lipidoses causes disease. According to one theory, the endocytic system's raft membranes expand due to the storage of glycosphingolipids, which can be a primary or secondary characteristic of abnormal metabolism. This results in the inappropriate retention of cell surface receptors that are typically involved in plasma membrane raft signaling events.

According to a second idea, stored glycosphingolipids (GSLs) do not only accumulate in the lysosome but may also severely affect typical homeostatic activities in other cellular membranes. This idea has been biochemically demonstrated in type 1 Gaucher disease, where examination of fractionated cells revealed the accumulation of GlcCer in numerous organelle membranes. This is also in line with the finding from electron microscopy investigations that the late endosomal/lysosomal system (LE/Lys) is not the only location where membranes in cells that store lipids have electron densities.

In order to enhance stem cell therapies for the treatment of some of the most crippling diseases of the modern era, CIRM and the German ministry are establishing the groundwork for collaborative research projects. Researchers from California and Germany gathered in San Francisco around the end of last year to talk about a variety of topics of interest. The discussions at that meeting indicated that cooperation in several fields, including the research of immunology, could be particularly beneficial.

The Germany market dominated the Europe Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $711.6 Million by 2028. The UK market is experiencing a CAGR of 4.8% during (2022 - 2028). Additionally, The France market would witness a CAGR of 6.5% during (2022 - 2028).

Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.

Scope of the Study

Market Segments covered in the Report:

By Disease Type

• Gaucher's Diseases
• Fabry Diseases
• Mucopolysaccharidosis
• Pompe’s Syndrome
• Others

By Type of Therapy

• Enzyme Replacement Therapy
• Substrate Reduction Therapy
• Stem Cell Therapy
• Others

By End User

• Hospitals
• Clinics
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Merck & Co., Inc.
• Johnson & Johnson (Janssen Global Services, LLC)
• Eli Lilly And Company
• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Novartis AG
• AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
• BioMarin Pharmaceutical Inc.
• Sigilon Therapeutics, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free